Progesterone Preeclampsia

Progesterone Supplementation for the Prevention of Preeclampsia

This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.

Inclusion Criteria:

• Pregnant individuals receiving prenatal care at participating clinics
• <12 weeks gestation with a viable intrauterine pregnancy
• Age ≥18 years
• English-speaking

Exclusion Criteria:

• Unable or unwilling to self-administer vaginal progesterone
• Inability or unwillingness to provide informed consent